OpenLB
Open Library of Bioscience
Advanced Search
Drugs & aging
04, 2019;36 (4): 341-354.

Clinical Outcomes Associated with Drug-Drug Interactions of Oral Chemotherapeutic Agents: A Comprehensive Evidence-Based Literature Review.

Manvi Sharma, Aisha Vadhariya, Soumya Chikermane, Suma Gopinathan, Mariana Chavez-MacGregor, Sharon H Giordano, Michael L Johnson, Holly M Holmes
Author Information
  1. Manvi Sharma: Department of Pharmacy Administration, The University of Mississippi, Oxford, MS, USA. msharma1@olemiss.edu.
  2. Aisha Vadhariya: Department of Pharmaceutical Health Outcomes and Policy, University of Houston, Houston, TX, USA.
  3. Soumya Chikermane: Department of Pharmaceutical Health Outcomes and Policy, University of Houston, Houston, TX, USA.
  4. Suma Gopinathan: Department of Pharmaceutical Health Outcomes and Policy, University of Houston, Houston, TX, USA.
  5. Mariana Chavez-MacGregor: Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  6. Sharon H Giordano: Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  7. Michael L Johnson: Department of Pharmaceutical Health Outcomes and Policy, University of Houston, Houston, TX, USA.
  8. Holly M Holmes: Department of Pharmaceutical Health Outcomes and Policy, University of Houston, Houston, TX, USA. ORCID
PMID: 30714077 DOI: 10.1007/s40266-019-00640-5

Abstract

BACKGROUND: Oral chemotherapy use is increasing due to new drug approvals as well as the convenience of the administration of oral drugs. This increased use also raises concern regarding drug-drug interactions (DDIs) with concomitantly administered drugs, resulting in loss of therapeutic effect, decreased tolerability, and/or increased toxicity.
OBJECTIVE: The objective of this study was to review existing evidence of the clinical impact of DDIs with oral chemotherapeutic agents.
METHODS: A comprehensive search of literature using PubMed was conducted in April 2018 for studies of DDIs associated with oral chemotherapy. Included studies were in English. We included randomized clinical trials, observational studies, and case reports evaluating a DDI between any oral chemotherapy drug and any other drug. Included studies needed to have at least one outcome of clinical relevance potentially attributed to the DDI, for example, effects on survival or toxicity. The quality of the articles was determined using published metrics appropriate for the study design.
RESULTS: There were 2626 studies identified in the initial search, of which 35 met all eligibility criteria. These included 15 retrospective cohort studies, 16 case reports or case series and four post hoc analyses of clinical trials. Among these, DDIs contributed to a statistically significant change in a clinical outcome in 12 studies. Eight of these studies evaluated overall survival and progression-free survival and found that the presence of the DDI was associated with reduced survival.
CONCLUSION: Our findings suggest that more real-world studies evaluating the association between oral chemotherapy DDIs and clinical outcomes are needed. The adverse clinical outcomes due to DDIs may be a reason for treatment failures and therapy discontinuation.

References

  1. Int J Clin Pharm. 2015 Dec;37(6):984-7 [PMID: 26394785]
  2. Ann Pharmacother. 2005 Jan;39(1):162-4 [PMID: 15546944]
  3. Cancer Lett. 2015 Dec 1;369(1):97-102 [PMID: 26341687]
  4. Cancer Chemother Pharmacol. 2012 Aug;70(2):345-50 [PMID: 22623211]
  5. J Oncol Pract. 2014 Jul;10(4):e255-68 [PMID: 24756141]
  6. J Oncol Pharm Pract. 2016 Jun;22(3):430-6 [PMID: 26152702]
  7. Gan To Kagaku Ryoho. 2015 Jul;42(7):833-9 [PMID: 26197745]
  8. J Geriatr Oncol. 2016 Sep;7(5):346-53 [PMID: 27498305]
  9. Oncol Nurs Forum. 2014 Mar 1;41(2):185-94 [PMID: 24370897]
  10. Ann Pharmacother. 2005 Sep;39(9):1546-51 [PMID: 16014372]
  11. BMJ Evid Based Med. 2018 Apr;23(2):60-63 [PMID: 29420178]
  12. Eur J Cancer. 2017 Nov;86:106-114 [PMID: 28985579]
  13. J Oncol Pharm Pract. 2019 Oct;25(7):1564-1569 [PMID: 30170514]
  14. J Res Pharm Pract. 2017 Jul-Sep;6(3):182-185 [PMID: 29026845]
  15. JAMA Oncol. 2017 Jun 1;3(6):767-773 [PMID: 27737436]
  16. J Chemother. 2005 Jun;17(3):339-42 [PMID: 16038530]
  17. Ann Hematol. 2010 Aug;89(8):783-7 [PMID: 20204361]
  18. J Am Geriatr Soc. 2015 Nov;63(11):2227-46 [PMID: 26446832]
  19. Nat Rev Clin Oncol. 2010 Jan;7(1):55-8 [PMID: 20029444]
  20. J Clin Pharm Ther. 2016 Feb;41(1):104-5 [PMID: 26813987]
  21. BMC Syst Biol. 2017 Oct 3;11(Suppl 5):87 [PMID: 28984210]
  22. Clin Lung Cancer. 2016 Sep;17(5):412-418 [PMID: 26944770]
  23. Age Ageing. 2015 Mar;44(2):213-8 [PMID: 25324330]
  24. Am J Health Syst Pharm. 2010 Sep 1;67(17):1426-9 [PMID: 20720241]
  25. J Oncol Pharm Pract. 2015 Jun;21(3):194-200 [PMID: 24664477]
  26. Clin Colorectal Cancer. 2006 Jan;5(5):354-8 [PMID: 16512995]
  27. Hepatogastroenterology. 2011 Jan-Feb;58(105):161-2 [PMID: 21510306]
  28. J Clin Pharm Ther. 2014 Jun;39(3):259-65 [PMID: 24417304]
  29. Sci Rep. 2016 Apr 18;6:24393 [PMID: 27087682]
  30. Am J Health Syst Pharm. 2007 May 1;64(9 Suppl 5):S8-S14 [PMID: 17468158]
  31. Am J Health Syst Pharm. 2014 Feb 1;71(3):200-3 [PMID: 24429012]
  32. Breast Cancer Res Treat. 2011 Jan;125(2):505-10 [PMID: 20593233]
  33. Invest New Drugs. 2012 Dec;30(6):2400-2 [PMID: 22116657]
  34. Br J Cancer. 2013 Mar 19;108(5):1071-8 [PMID: 23412102]
  35. Clin Lung Cancer. 2015 Jan;16(1):33-9 [PMID: 25246385]
  36. BMJ. 2010 Feb 08;340:c693 [PMID: 20142325]
  37. J Clin Oncol. 1984 May;2(5):396-405 [PMID: 6726294]
  38. Clin Genitourin Cancer. 2017 Dec;15(6):724-732 [PMID: 28645482]
  39. Lancet. 2000 Jul 22;356(9226):285-90 [PMID: 11071183]
  40. Oncotarget. 2016 Dec 20;7(51):85542-85550 [PMID: 27907909]
  41. Cancer Chemother Pharmacol. 2016 Aug;78(2):427-32 [PMID: 27372908]
  42. Am J Health Syst Pharm. 2009 Dec 1;66(23):2123-5 [PMID: 19923313]
  43. Cancer Chemother Pharmacol. 2017 Nov;80(5):945-954 [PMID: 28932966]
  44. Leukemia. 1994 Jul;8(7):1113-5 [PMID: 8035603]
  45. Lung Cancer. 2013 Oct;82(1):136-42 [PMID: 23910908]
  46. PLoS One. 2016 Feb 19;11(2):e0149722 [PMID: 26894507]

Grants

  1. P30 CA016672/NCI NIH HHS

MeSH Term

Administration, Oral
Antineoplastic Combined Chemotherapy Protocols
Cohort Studies
Drug Interactions
Humans
Neoplasms
Retrospective Studies
Treatment Outcome
Journal Article Research Support, N.I.H., Extramural Systematic Review
Article has an altmetric score of 3

Word Cloud

Created with Highcharts 10.0.0studiesclinicalDDIsoralchemotherapysurvivaldrugcaseDDIOraluseduedrugsincreasedtoxicitystudysearchusingassociatedIncludedincludedtrialsreportsevaluatingneededoutcomeoutcomesBACKGROUND:increasingnewapprovalswellconvenienceadministrationalsoraisesconcernregardingdrug-druginteractionsconcomitantlyadministeredresultinglosstherapeuticeffectdecreasedtolerabilityand/orOBJECTIVE:objectivereviewexistingevidenceimpactchemotherapeuticagentsMETHODS:comprehensiveliteraturePubMedconductedApril2018EnglishrandomizedobservationalleastonerelevancepotentiallyattributedexampleeffectsqualityarticlesdeterminedpublishedmetricsappropriatedesignRESULTS:2626identifiedinitial35meteligibilitycriteria15retrospectivecohort16seriesfourposthocanalysesAmongcontributedstatisticallysignificantchange12Eightevaluatedoverallprogression-freefoundpresencereducedCONCLUSION:findingssuggestreal-worldassociationadversemayreasontreatmentfailurestherapydiscontinuationClinicalOutcomesAssociatedDrug-DrugInteractionsChemotherapeuticAgents:ComprehensiveEvidence-BasedLiteratureReview

Similar Articles

Cited By